Skip to main content

Mouse CCL5/RANTES Antibody Best Seller

R&D Systems, part of Bio-Techne | Catalog # MAB478

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB478-100
MAB478-500
MAB478-SP

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Mouse

Cited:

Human, Mouse, Rat

Applications

Validated:

Immunocytochemistry, Neutralization

Cited:

Bioassay, ELISA Development, ELISA Development (Capture), Immunocytochemistry, Immunohistochemistry-Frozen, In vivo assay, Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2A Clone # 53405

Product Specifications

Immunogen

E. coli-derived recombinant mouse CCL5/RANTES
Ser24-Ser91
Accession # P30882

Specificity

Detects mouse CCL5/RANTES in direct ELISAs. Shows 50% cross-reactivity with recombinant human (rh) CCL5, and no cross-reactivity with recombinant feline CCL5, rhCCL3, recombinant mouse (rm) CCL3, rmCCL4, rhCCL4, rhCCL14, or rhCCL18.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Mouse CCL5/RANTES Antibody

CCL5/RANTES antibody in Mouse Splenocytes by Immunocytochemistry (ICC).

CCL5/RANTES in Mouse Splenocytes.

CCL5/RANTES was detected in immersion fixed mouse splenocytes using Mouse CCL5/RANTES Monoclonal Antibody (Catalog # MAB478) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (red; Catalog # NL013) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Chemotaxis Induced by CCL5/RANTES and Neutralization by Mouse CCL5/RANTES Antibody.

Chemotaxis Induced by CCL5/RANTES and Neutralization by Mouse CCL5/RANTES Antibody.

Recombinant Mouse CCL5/RANTES (Catalog # 478-MR) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse CCL5/RANTES (0.025 µg/mL) is neutralized (green line) by increasing concentrations of Mouse CCL5/RANTES Monoclonal Antibody (Catalog # MAB478). The ND50 is typically 0.1-0.5 µg/mL.
Detection of Mouse CCL5/RANTES by Immunohistochemistry

Detection of Mouse CCL5/RANTES by Immunohistochemistry

Antagonizing RANTES within CNS extends the survival of mice after TBEV infection. Mice were treated with Met-RANTES, vehicle, anti-RANTES mAb, or isotype-matched control Ab daily from day 2 to 8 after a primary TBEV infection. a Met-RANTES-treated mice exhibited a delay in mortality following lethal TBEV challenge. Mortality in each group was monitored daily for 14 days. Data were pooled from three independent experiments (total of approximately 18 mice per group). Statistical differences were evaluated using the Kaplan–Meier test for mortality. *P < 0.05, compared to vehicle-treated mice. b Anti-RANTES mAb-treated mice exhibited a delay in mortality following lethal TBEV challenge. Mortality in each group was monitored daily for 14 days. Data were pooled from three independent experiments (total of approximately 18 mice per group). *P < 0.05, compared to isotype Ab-treated mice. c, d Body weight changes of mice were monitored daily. For each time point, the measured values are the average of the surviving mice. Bars represent the means ± the standard deviations of three independent experiments (total of approximately 18 mice per group). e Infectious virus in brain tissues. No significant difference in virus titers was observed at day 2, 5, or 8 between Met-RANTES-treated mice and vehicle-injected mice or anti-RANTES mAb-treated and isotype Ab-injected mice. Bars represent the means ± the standard deviations of three independent experiments (n = 4 mice per group). NS not significant. f Met-RANTES or anti-RANTES mAb treatment reduced inflammatory cell accumulation (indicated by black arrows) in cerebral cortex sections, compared to results for vehicle- or isotype Ab-treated mice, respectively. The histopathological changes of PFA-fixed sections in cerebral cortex were examined by HE staining on day 8 p.i. The photomicrographs demonstrate representative images obtained from three independent experiments (n = 4 mice per group). Bars, 100 μm Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0665-9), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Mouse CCL5/RANTES Antibody

Application
Recommended Usage

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed mouse polymorphonuclear cells and mouse splenocytes

Neutralization

Measured by its ability to neutralize CCL5/RANTES-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR5. The Neutralization Dose (ND50) is typically 0.1-0.5 µg/mL in the presence of 0.025 µg/mL Recombinant Mouse CCL5/RANTES.

Reviewed Applications

Read 3 reviews rated 4.7 using MAB478 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL5/RANTES

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta-chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1-3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature mouse CCL5 shares 100% amino acid (aa) sequence identity with rat CCL5 and 75-88% with canine, cotton rat, feline, and human CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11-13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14-16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of pro-inflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).

References

  1. Schall, T.J. et al. (1990) Nature 347:669.
  2. Bacon, K.B. et al. (1995) Science 269:1727.
  3. Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
  4. Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
  5. Heeger, P. et al. (1992) Kidney Int. 41:220.
  6. Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
  7. Levy, J.A. (2009) J. Immunol. 182:3945.
  8. Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
  9. DeVico, A.L. and R.C. Gallo (2004) Nat. Rev. Microbiol. 2:401.
  10. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
  11. Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
  12. Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. USA 100:1885.
  13. von Hundelshausen, P. et al. (2005) Blood 105:924.
  14. von Hundelshausen, P. et al. (2001) Circulation 103:1772.
  15. Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
  16. Baltus, T. et al. (2003) Blood 102:1985.
  17. Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.

Alternate Names

RANTES, SISd

Entrez Gene IDs

6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline)

Gene Symbol

CCL5

UniProt

Additional CCL5/RANTES Products

Product Documents for Mouse CCL5/RANTES Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Mouse CCL5/RANTES Antibody

For research use only

Loading...
Loading...
Loading...
Loading...